Arcturus Therapeutics Holdings Inc. Operating Income Loss

• Arcturus Therapeutics Holdings Inc. showed an increase of +20.3% in Operating Income Loss from 2024 to 2025.
• This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Arcturus Therapeutics Holdings Inc.'s Operating Income Loss has declined by 249.6%.
• Historical annual values: Fiscal year 2025: -$76.26 million | Fiscal year 2024: -$95.67 million | Fiscal year 2023: -$78.21 million | Fiscal year 2022: $12.18 million | Fiscal year 2021: -$202.85 million | Fiscal year 2020: -$71.52 million | Fiscal year 2019: -$25.51 million | Fiscal year 2018: -$21.81 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026